The first cross strait biotechnology and new drug industry cooperation forum was held in Taipei

The forum was jointly held by China pharmaceutical innovation promotion association and Taiwan biotechnology and medical industry promotion association The two sides signed a memorandum of cooperation, aiming to build a platform for further strengthening exchanges and cooperation between pharmaceutical enterprises across the Taiwan Strait Chen Weizhao, President of Taiwan biotechnology and medical industry strategy Association, said at the forum that Taiwan has abundant and high-quality clinical and R & D talents, and the relevant industry incentive promotion policy environment is good In recent years, the mainland has actively arranged new drug R & D, with a large production scale Therefore, both sides of the Straits have strong complementarities in new drug research and development, clinical and production systems, with a great space for cooperation, and also have the opportunity to jointly enter the international market Song Ruilin, executive chairman of China pharmaceutical innovation promotion association, said the forum arranged nearly 40 cross-strait innovative pharmaceutical enterprises talks, looking forward to promoting substantive cooperation between cross-strait pharmaceutical enterprises It is reported that this is the first time that 11 innovative pharmaceutical enterprises in mainland China, including Hengrui pharmaceutical, Meiluo pharmaceutical, Chengdu Kanghong, Tianshili and other famous pharmaceutical enterprises, have come to Taiwan collectively to implement the key projects of the 12th Five Year Plan Related reports: Lu 11 pharmaceutical factory organized a group to visit their families in Taiwan [economic daily / reporter Huang Wenqi / Taipei report]
2014.11.10 03:06 am
Mainland pharmaceutical companies came to Taiwan in a group, and the two sides of the Taiwan Strait had a big match in biotechnology On October 10, the National Biotechnology and medical industry promotion association, a legal entity, will set up a platform to hold the "2014 cross strait biotechnology and new drug industry cooperation forum" Shengce said that there will be 11 major pharmaceutical companies in the mainland and more than 30 cross-strait cooperation meetings, the first case of large-scale cross-strait cooperation in the pharmaceutical industry According to the health policy committee, the 11 pharmaceutical companies invited in the mainland are all the pharmaceutical enterprises supported by the state, including Hengrui pharmaceutical, Meiluo pharmaceutical, Shanghai Pharmaceutical Group, and Xiansheng pharmaceutical They are all the first to come to Taiwan to find partners, and discuss with major new drug R & D enterprises in Taiwan about the opportunities, key areas, and how to link international laws and clinical trials 。
In terms of purpose, the health policy committee pointed out that since the "cross strait medical and health cooperation agreement" has been signed for many years, the government has not taken any further action It is necessary for the people to take the lead to promote cross-strait new drug research and development and jointly layout the international market This time, China pharmaceutical promotion association will work together to build a platform and hope to recruit relatives for both sides Taiwan's participating biotech companies, including Zhang Nianci, chairman of Haoding, Lin Rongjin, chairman of Shengde, Tang Junjun, vice president of Quansheng, Wu Bowen, executive director of Ruihua, ye Zhihong, general manager of Taiwan microbody and other leaders of innovative biotech companies, will attend the meeting As for the mainland, song Ruilin, executive chairman of China pharmaceutical promotion association, Liu Yanjun, vice president of Shanghai Pharmaceutical Group, Liu Ming, executive director of Hengrui pharmaceutical, Yin Jinqun, vice president of Chengdu Kanghong pharmaceutical, Yu Guoliang, chairman of Sino US Guanke, etc are all the time choices of the mainland pharmaceutical industry In terms of cross-strait biotechnology cooperation, Zhang Nianci, chairman of Haoding, said that Taiwan's advantages lie in clinical, talent, laws and regulations, and clinical aspects Taiwan has international experience, and the standard unified closing meeting of various hospitals is relatively smooth In addition, Shanghai has a large pool of surgical research talents, strong research and development energy, and experience in developing successful products In addition, Taiwan's biotechnology laws and regulations are still superior to those of the mainland In terms of the advantages of the mainland, there are many people and a large market, and the clinical treatment is fast The government is very considerate in supporting and protecting the industry For them, of course, it is also an advantage Zhang Nianci stressed that the two sides should not compete but cooperate now, perhaps not talk about the high-profile of "joining hands to enter the international market", but should pay attention to how to improve the industrial objectives and make the industry work together with mutual benefit and reciprocity based on the advantages of both sides Lin Rongjin, chairman of Shengde, pointed out that in the past, when cross-strait companies cooperated, Taiwan could not exceed 51% of the shares Now the ban has been lifted in succession, but it should be more open in the future Secondly, many companies in the mainland are short-sighted and like to whitewash Taiping Compared with Taiwan, they lack a sense of social responsibility, which needs to be corrected.